Aptorum Group Limited (NASDAQ:APM) Short Interest Update

Aptorum Group Limited (NASDAQ:APM) was the recipient of a significant decline in short interest in the month of December. As of December 31st, there was short interest totaling 2,681 shares, a decline of 75.1% from the December 15th total of 10,748 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average daily volume of 61,744 shares, the days-to-cover ratio is currently 0.0 days. Based on an average daily volume of 61,744 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.1% of the company’s shares are short sold.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Wall Street Zen raised shares of Aptorum Group from a “sell” rating to a “hold” rating in a research report on Saturday, October 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aptorum Group in a report on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Aptorum Group Price Performance

Shares of APM stock opened at $1.06 on Thursday. Aptorum Group has a 1-year low of $0.69 and a 1-year high of $4.47. The stock has a 50-day moving average of $1.25 and a 200-day moving average of $1.51.

About Aptorum Group

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.